MANUFACTURING FOR TOMORROW’S MEDICINES, TODAY.
NTx has re-imagined how biomanufacturing can be done, using a proprietary, easily scalable, continuous flow, cell-free system that fits on a benchtop or in a small isolator glovebox, with the goal of democratizing the production of RNA and proteins, to enable global access to the next generation of vaccines and therapeutics.
Using our proprietary enzymes and bioreactor systems, we can make RNA (including mRNA, saRNA, etc.) in a fraction of the time and cost, simultaneously decreasing purification and other associated costs using traditional bioprocessing methods. The technology systems are also efficiently tunable, making them useful to address product updates that may be needed (e.g. to address new virus variants, like in COVID). The technology enables R&D and clinical production of next-generation therapeutic modalities, like self-amplifying RNA, which are incredibly difficult to manufacture using commercially available equipment and processes.TECHNOLOGIES
Powering Advancements in Medicine and Patient Access
NTx is redefining the discovery and production of biologic materials to be infinitely faster, purer and more affordable for everyone with breakthrough advances in cell-free (CF) biomanufacturing. We’re moving beyond empowering biopharma to impact global health and humanity.
While cell-free manufacturing was established decades ago, our platforms are scalable to rapidly support clinical trials and ultimately to fuel global supply chains. We help researchers innovate faster and we are committed to helping companies increase and streamline production as they respond to changing global demand.